Atrial Fibrillation

This channel includes news and new technology innovations for the treatment of atrial fibrillation, also referred to as AF or afib. AF is a cardiac arrhythmia caused by irregular and often rapid heart rate. It is caused by the upper chambers (the atria) beating irregularly and uncoordinated with the lower  ventricle chambers of of the heart. Symptoms include weakness with heart palpitations and shortness of breath. The conditional can lead to an increased risk of stroke and heart failure. AF episodes can cause the blood in the atria to stagnate and form clots, usually within the left atrial appendage (LAA). The clots can flow to the brain and cause a stroke. Treatments include anticoagulation therapy to dissolve clots, catheter or surgical ablation and LAA occlusion

Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018

May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral...

Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group

News | Atrial Fibrillation | May 18, 2018

 

May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in...

Heart Rhythm Society (HRS) live electrophysiology (EP) procedure case at the 2018 annual meeting. #HRS2018

A live EP case presentation during the 2018 Heart Rhythm meeting.

Feature | HRS | May 18, 2018 | Dave Fornell

Here is an aggregation of all the news and late-breaking studies presented at the 2018...

Atrial fibrillation ablation using the Abbott Ensite electro mapping system. CABANA Trial Confirms Ablation Equal To or Superior to Drug Therapy. #HRS2018

Atrial fibrillation ablation using the Abbott Ensite electro mapping system.

Feature | Atrial Fibrillation | May 17, 2018

May 16, 2018 – The first results of the randomized, multicenter, long-term, international...

CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018

May 17, 2018 — Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its...

Itamar Medical Launches SleePath for AFib Patients at Heart Rhythm 2018
Technology | Patient Monitors | May 16, 2018

May 16, 2018 — Itamar Medical Ltd. announced the launch of SleePath, the first integrated e-health sleep apnea care...

Link Found Between Post-Traumatic Stress, Increased Risk of AFib. #HRS2018
News | Atrial Fibrillation | May 15, 2018

May 15, 2018 — A new study is the first to report a relationship between post-traumatic stress disorder (PTSD) and...

Marijuana Use Does Not Increase Risk of Arrhythmias, Might Reduce AFib Risk. #HRS2018
News | Atrial Fibrillation | May 15, 2018

May 15, 2018 — According to new research, smoking marijuana may not be associated with an increased risk of...

First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception...

New Combined Risk Score More Effectively Predicts Stroke Risk in AFib Patients

Image courtesy of Intermountain Medical Center Heart Institute

News | Atrial Fibrillation | May 11, 2018

May 11, 2018 — A new ...

Online ECG Monitoring Detects Paroxysmal AFib More Effectively Than Holter, Patch Methods
News | ECG Monitoring Services | May 09, 2018

May 9, 2018 – Medicalgorithmics S.A. will present the results of a large...

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first...

The Abbott Advisor HD Grid Mapping Catheter, Sensor Enabled, allows high density electro mapping for transcatheter EP cardiac ablation procedures.
Technology | EP Mapping and Imaging Systems | May 03, 2018

May 3, 2018 — The U.S. Food and Drug Administration (FDA) has granted market clearance for the Abbott Advisor HD...

Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018

April 12, 2018 — Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of...

Overlay Init